Skip to main content

Find a clinical trial

G1T48-01

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (G1T48-01) Philippe Aftimos

IMpassion 030 (BIG 16-05/AFT-27/WO39391)

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer Michail Ignatiadis

WO40324

A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in combination with chemotherapy in patients with HER2-positive early breast cancer Evandro De Azambuja

ODO-TE-B301, CONTESSA

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane Andrea Gombos

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos

B PRECISE 01

Open-label, multicentre, phase Ib dose escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab +/- fulvestrant, in subjects with PIK3CA mutated HER2-positive locally recurrent unresectable (advanced) or metastatic (a/m) breast cancer progressed to anti-HER2 based therapy Philippe Aftimos

BAY 88-8223 / 16996

A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride Géraldine Gebhart

APPALACHES

A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES) Lissandra Dal Lago

IJB-SYNERGY-012017

A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer. Synergy Trial (IJB-SYNERGY-012017) Philippe Aftimos

TOUCH

Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer (IBCSG 55-17 / TOUCH) Andrea Gombos

DS8201-A-U302

DS8201-A-U302 A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer Andrea Gombos

DS8201-A-U303

A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of Physician's choice for HER2-low, HR-positive, unresectable and/or metastatic breast cancer subjects (DS8201-A-U303) Andrea Gombos

KEYNOTE-756

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756) Andrea Gombos

EMERALD

Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial Philippe Aftimos

IMBrella

An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) Ahmad Hussein Awada

NATALEE

A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)(CLEE011O12301C (TRIO033)) Andrea Gombos

ZEN003694-004

A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer Philippe Aftimos

ICON

A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer Andrea Gombos

IMMU-132-09

Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens Philippe Aftimos

IJB-LBC-NEOCHECKRAY-2018

Neo-adjuvant chemotherapy combined with SBRT to the primary tumor +/- durvalumab +/- oleclumab in luminal B breast cancer: a phase ll randomized trial Laurence Buisseret